Replimune Group Stock Price, News & Analysis (NASDAQ:REPL) $12.32 +0.61 (+5.21%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$11.35▼$12.3850-Day Range$10.18▼$17.1152-Week Range$9.79▼$29.52Volume823,164 shsAverage Volume623,235 shsMarket Capitalization$727.62 millionP/E RatioN/ADividend YieldN/APrice Target$51.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Replimune Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside316.7% Upside$51.33 Price TargetShort InterestHealthy17.01% of Float Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.50Based on 4 Articles This WeekInsider TradingSelling Shares$187,072 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.53) to ($3.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.47 out of 5 starsMedical Sector226th out of 952 stocksBiological Products, Except Diagnostic Industry27th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.33, Replimune Group has a forecasted upside of 316.7% from its current price of $12.32.Amount of Analyst CoverageReplimune Group has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted17.01% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Replimune Group has recently decreased by 15.48%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreReplimune Group has received a 69.41% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for Replimune Group is -1.28. Previous Next 2.5 News and Social Media Coverage News SentimentReplimune Group has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Replimune Group this week, compared to 2 articles on an average week.Search Interest4 people have searched for REPL on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $187,072.00 in company stock.Percentage Held by Insiders20.60% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Replimune Group are expected to decrease in the coming year, from ($3.53) to ($3.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Replimune Group Stock (NASDAQ:REPL)Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Read More REPL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REPL Stock News HeadlinesDecember 3, 2023 | americanbankingnews.comReplimune Group (NASDAQ:REPL) Stock Price Down 3.4%December 3, 2023 | americanbankingnews.comReplimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Buy" by BrokeragesDecember 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 2, 2023 | americanbankingnews.comReplimune Group Sees Unusually Large Options Volume (NASDAQ:REPL)November 26, 2023 | benzinga.comReplimune Group Stock (NASDAQ:REPL) Dividends: History, Yield and DatesNovember 24, 2023 | benzinga.comReplimune Group Stock (NASDAQ:REPL), Analyst Ratings, Price Targets, PredictionsNovember 8, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Scholar Rock Holding (SRRK), Replimune Group (REPL) and Precision BioSciences (DTIL)November 8, 2023 | finance.yahoo.comReplimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma ResearchDecember 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 7, 2023 | msn.comReplimune Group GAAP EPS of -$0.90 misses by $0.04November 7, 2023 | finance.yahoo.comReplimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate UpdateNovember 5, 2023 | seekingalpha.comReplimune: Skepticism Is Priced In Ahead Of Long-Awaited CERPASS Data (Rating Upgrade)November 3, 2023 | finance.yahoo.comReplimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)November 2, 2023 | morningstar.comReplimune Group Inc REPLSeptember 14, 2023 | finance.yahoo.comInsider Sell: Pamela Esposito Sells 5,658 Shares of Replimune Group IncSeptember 10, 2023 | fool.comReplimune Group (NASDAQ: REPL)August 14, 2023 | msn.comReplimune: Q4 2023 Data Readouts Of RP1 Makes This A Must WatchAugust 9, 2023 | msn.comUnusual Put Option Trade in Replimune Group (REPL) Worth $810.00KAugust 8, 2023 | markets.businessinsider.comArvinas Holding Company (ARVN) Receives a Buy from BarclaysAugust 3, 2023 | finance.yahoo.comReplimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate UpdateAugust 1, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Replimune GroupJuly 31, 2023 | finance.yahoo.comReplimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell CarcinomaJuly 20, 2023 | finance.yahoo.comReplimune Announces Sander Slootweg will Depart from its Board of DirectorsJuly 13, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Replimune Group (REPL)July 9, 2023 | msn.comReplimune: The Rise Of Oncolytic Virus Therapies In Cancer TreatmentJune 28, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Aldeyra Therapeutics (ALDX), Replimune Group (REPL)June 9, 2023 | msn.comHC Wainwright & Co. Reiterates Replimune Group (REPL) Buy RecommendationSee More Headlines Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/05/2023Next Earnings (Estimated)2/08/2024Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:REPL CUSIPN/A CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees284Year Founded2015Price Target and Rating Average Stock Price Target$51.33 High Stock Price Target$70.00 Low Stock Price Target$34.00 Potential Upside/Downside+316.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-174,280,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.28% Return on Assets-31.87% Debt Debt-to-Equity Ratio0.11 Current Ratio12.76 Quick Ratio12.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.80 per share Price / Book1.26Miscellaneous Outstanding Shares59,060,000Free Float46,893,000Market Cap$727.62 million OptionableNot Optionable Beta1.45 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Philip Astley-Sparke F.S.A. (Age 52)CEO & Director Comp: $1.07MDr. Sushil Patel Ph.D. (Age 52)Chief Strategy Officer Comp: $665.05kDr. Robert Coffin Ph.D. (Age 58)Founder, President, Chief Research & Development Officer and Director Comp: $785.89kMs. Emily Luisa Hill (Age 43)Chief Financial Officer Dr. Colin A. Love Ph.D. (Age 65)Chief Operating Officer Comp: $419.37kMr. Andrew Schwendenman (Age 47)Chief Accounting Officer & Treasurer Dr. Pamela Esposito Ph.D. (Age 49)Chief Business Officer Comp: $464.63kMs. Tanya N. Lewis M.S. (Age 52)Chief Development Operations Officer Comp: $4.7kMr. Christopher Sarchi (Age 55)Chief Commercial Officer Dr. Konstantinos Xynos M.B.A. (Age 57)M.D., Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsNovavaxNASDAQ:NVAXHilleVaxNASDAQ:HLVXPrime MedicineNYSE:PRMEImmaticsNASDAQ:IMTXAmbrx BiopharmaNYSE:AMAMView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 52,633 shares on 12/1/2023Ownership: 0.442%American Century Companies Inc.Bought 7,703 shares on 11/30/2023Ownership: 0.052%Deutsche Bank AGSold 116,726 shares on 11/24/2023Ownership: 0.032%Graham Capital Management L.P.Bought 19,867 shares on 11/22/2023Ownership: 0.034%Konstantinos XynosSold 7,313 sharesTotal: $79,857.96 ($10.92/share)View All Insider TransactionsView All Institutional Transactions REPL Stock Analysis - Frequently Asked Questions Should I buy or sell Replimune Group stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REPL shares. View REPL analyst ratings or view top-rated stocks. What is Replimune Group's stock price target for 2024? 6 brokerages have issued 1-year target prices for Replimune Group's shares. Their REPL share price targets range from $34.00 to $70.00. On average, they expect the company's share price to reach $51.33 in the next year. This suggests a possible upside of 316.7% from the stock's current price. View analysts price targets for REPL or view top-rated stocks among Wall Street analysts. How have REPL shares performed in 2023? Replimune Group's stock was trading at $27.20 at the start of the year. Since then, REPL stock has decreased by 54.7% and is now trading at $12.32. View the best growth stocks for 2023 here. When is Replimune Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024. View our REPL earnings forecast. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) posted its earnings results on Tuesday, November, 7th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by $0.10. What ETFs hold Replimune Group's stock? ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Horizon Kinetics Medical ETF (MEDX), First Trust Innovation Leaders ETF (ILDR).ALPS Medical Breakthroughs ETF (SBIO), What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC). When did Replimune Group IPO? (REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. Who are Replimune Group's major shareholders? Replimune Group's stock is owned by a number of institutional and retail investors. Top institutional investors include Redmile Group LLC (7.05%), Loomis Sayles & Co. L P (2.19%), FMR LLC (2.15%), Emerald Advisers LLC (1.78%), Emerald Mutual Fund Advisers Trust (1.48%) and Northern Trust Corp (0.77%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Konstantinos Xynos, Pamela Esposito, Philip Astley-Sparke, Robert Coffin, Sushil Patel and Tanya Lewis. View institutional ownership trends. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:REPL) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.